Robotic-assisted thoracoscopic segmentectomy increases lymph node stations examined and reduces hospital stay durationRobotic surgery may help lung cancer patients stay in hospital less

This meta-analysis evaluated the comparative efficacy and safety of robotic-assisted thoracoscopic segmentectomy (RATS) versus video-assisted thoracoscopic segmentectomy (VATS) in a large cohort of 19,805 patients diagnosed with early-stage non-small cell lung cancer (NSCLC). The study specifically focused on surgical techniques used during segmentectomy to determine if robotic assistance influenced perioperative outcomes and the thoroughness of nodal station assessment.

The primary comparison involved RATS versus VATS. While specific dosing or procedural protocols were not detailed in the meta-analysis, the analysis focused on the technical differences between the two minimally invasive approaches for treating early-stage NSCLC. The study aimed to quantify differences in surgical efficiency and oncologic staging accuracy.

Regarding the primary outcomes of perioperative results and nodal assessment, RATS was associated with a significantly greater number of lymph node stations examined compared to VATS (WMD = 1.16; 95% CI: 0.51, 1.81; P < 0.001). Additionally, patients undergoing RATS experienced a shorter length of hospital stay (WMD = -0.75; 95% CI: -1.36, -0.15; P = 0.015) compared to those undergoing VATS.

Several secondary outcomes were analyzed to determine if the robotic platform impacted surgical time or complication rates. There was no significant difference in operative time between RATS and VATS (WMD = 1.86; 95% CI: -8.80, 12.52; P = 0.732). Similarly, there was no significant difference in the duration of drainage (WMD = -0.37; 95% CI: -0.79, 0.06; P = 0.090).

Safety and complication profiles were also compared between the two techniques. No significant differences were observed in overall complications (OR = 0.94; 95% CI: 0.67, 1.34; P = 0.745), air leak rates (OR = 1.02; 95% CI: 0.54, 1.91; P = 0.949), or pneumonia rates (OR = 1.33; 95% CI: 0.89, 1.99; P = 0.170). Furthermore, the rate of 30-day readmission showed no significant difference between RATS and VATS (OR = 1.09; 95% CI: 0.94, 1.26; P = 0.257).

These results suggest that while RATS may offer advantages in the precision of lymph node assessment and potentially faster recovery times, it does not appear to increase the risk of common surgical complications compared to VATS. However, these findings are based on retrospective data, meaning an association is observed rather than a proven cause.

Methodological limitations include a notable risk of bias inherent in the included studies and a lack of evidence regarding oncologic superiority. Because the study relies on retrospective data, the certainty of these results is limited. Clinicians should consider that while RATS may improve surgical metrics like lymph node count and hospital stay, it has not been proven to provide superior oncologic outcomes for NSCLC patients. Future research must address whether the increased number of lymph node stations examined translates into improved long-term survival or progression-free intervals. Currently, the data supports RATS as a viable alternative to VATS with comparable safety profiles and specific benefits in surgical thoroughness.